Abstract
There is much uncertainty about the mechanism of action of paracetamol (acetaminophen). It is commonly stated that, unlike the non-steroidal anti-inflammatory drugs (NSAIDs), it is a weak inhibitor of the synthesis of prostaglandins. This conclusion is made largely from studies in which the synthesis of prostaglandins was measured in homogenized tissues. However, in several cellular systems, paracetamol is an inhibitor of the synthesis of prostaglandins with IC50 values ranging from approximately 4 µM to 200 µM. Paracetamol is not bound significantly to plasma proteins and therefore the concentrations in plasma can be equated directly with those used in in vitro experiments. After oral doses of 1 g, the peak plasma concentrations of paracetamol are approximately 100 µM and the plasma concentrations are therefore in the range where marked inhibition of the synthesis of prostaglandins should occur in some cells. Paracetamol is metabolized by the peroxidase component of prostaglandin H synthase but the relationship of this to inhibition of the cyclooxygenase or peroxidase activities of the enzyme is unclear. Paracetamol is also metabolized by several other peroxidases, including myeloperoxidase, the enzyme in neutrophils which is responsible for the production of hypochlorous acid (HOCl). The metabolism of paracetamol by myeloperoxidase leads to the decreased total production of HOC1 by both intact neutrophils and isolated myeloperoxidase, even though the initial rate of production of HOC1 is increased. The IC50 value, derived from inhibition of the total production of HOC1 by isolated myeloperoxidase, is 81 µM. Several NSAIDs inhibit functions of neutrophils in media containing low concentrations of protein but their effects, in contrast to that of paracetamol, are generally produced only at concentrations greater than those of the unbound drug in plasma during treatment with the NSAIDs. However, neutrophils isolated during treatment with NSAIDs, such as piroxicam, ibuprofen and indomethacin show decreased function. Paracetamol has little or no anti-inflammatory activity by itself but may potentiate the clinical activity of NSAIDs in the treatment of rheumatoid arthritis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benet, L. Z., Øie, S. and Schwartz, J. B. (1996). Design and optimization of dosage regimens; pharmacokinetic data, in: Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Hardman, J. G. and Limbird, L. E. (Eds), pp. 1707-1792. McGraw-Hill, New York.
Biemond, P., Han, H., Swaak, A. J. G. and Koster, J. F. (1990). Diminished Superoxide production of synovial fluid neutrophils in patients with rheumatid arthritis following piroxicam treatment, Scand. J. Rheumatol. 19, 151–156.
Bradley, J. D., Brandt, K. D., Katz, B. P., Kalasinski, L. A. and Ryan S. I. (1991). Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatmment of patients with osteoarthritis of the knee, New Engl. J. Med. 325, 87–91.
Brune, K. and Peskar, B. A. (1980). Paracetamol does not potentiate the acetylsalicylate inhibition of prostaglandin release from macrophages, Eur. J. Pharmacol. 68, 365–367.
Brune, K., Rainsford, K. D., Wagner, K. and Peskar, B. A. (1981). Inhibition by anti-inflammatory drugs of prostaglandin production in cultured macrophages, Naunyn-Schmiedeberg’s Arch. Pharmacol. 315, 269–278.
Ferrari, R. A, Ward, S. J., Zobre, C. M., Van Liew, D. K., Perrone, M. H., Connell, M. J. and Haubrich, D. R. (1990). Estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2 levels in mouse brain, Eur. J. Pharmacol. 179, 25–34.
Flower, R. J. and Vane, J. R. (1972). Inhibition of prostglandin synthetase in brain explains the antipyretic activity of paracetamol (4-acetamidophenol), Nature 240, 410–411.
Friman, C., Johnston C., Chew, C. and Davis, P. (1986). Effect of diclofenac sodium, tolfenamic acid and indomethacin on the production of Superoxide induced by N-formyl-methionyl-leucyl-phenylalanine in normal human polymorphonuclear leukocytes, Scand. J. Rheumatol. 15, 41–46.
Graham, G. G., Milligan, M. K., Day, R. O., Williams, K. M. and Ziegler, J. B. (1997). Therapeutic considerations from pharmacokinetics and metabolism: ibuprofen and paracetamol, in: Safety and Efficacy of Non-prescription (Over-the-Counter) Analgesics and NSAIDs, Rainsford, K. D. and Powanda, M. C. (Eds), pp. 77–92. Kluwer Press, Dordrecht.
Hanel, A. M. and Lands, W. E. M. (1982). Modification of anti-inflammatory drug effectiveness by ambient lipid peroxides, Biochem. Pharmacol. 31, 3307–3311.
Harvison, P. J., Egan, R. W., Gale, R. H., Christian, G. D., Hill, B. S. and Nelson, S. D. (1988). Acetaminophen and analogs as cosubstrates and inhibitors of prostaglandin H synthase, Chemico-Biological Interactions. 64, 251–266.
Insel, P. A. (1996). Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout, in: Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Hardman, J. G. and Limbird, L. E. (Eds), pp. 617–657. McGraw-Hill, New York.
Kaplan, H. B., Edelson, H. S., Korchak, H. M., Given, W. P., Abramson, S. and Weissmann, G. (1984). Effects of non-steroidal anti-inflammatory agents on human neutrophils functions in vitro and in vivo, Biochem. Pharmacol. 33, 371–378.
Lages, B. and Weiss, H. J. (1989). Inhibition of human platelet function in vitro and ex vivo by acetaminophen, Thrombosis Research 53, 603–613.
Landolfi, C., Soldi, L., Polenzani, L., Apicella, C., de Joannon, A. C., Coletta, I. et al. (1998). Inflammatory molecule release by β amyloid-treated T98G astrocytoma cells: role of prostaglandins and modulation by paracetamol, Eur. J. Pharmacol. 360, 55–64.
Lanz, R., Polster, P. and Brune, K. (1986). Antipyretic analgesics inhibit prostaglandin release from astrocytes and macrophages similarly, Eur. J. Pharmacol. 130, 105–109.
Malmberg, A. B. and Yaksh, T. L. (1994). Capsaicin-evoked prostaglandin E2 release in spinal cord slices: relative effect of cyclooxygenase inhibitors, Eur. J. Pharmacol. 271, 293–299.
Potter, D. W. and Hinson, J. A. (1987). The 1- and 2-electron oxidation of acetaminophen catalyzed by prostaglandin H synthase, J. Biol Chem. 262, 974–980.
Seideman, P. (1993). Additive effect of combined naproxen and paracetamol in rheumatoid arthritis, Brit. J. Rheumatol. 32, 1077–1082.
Thompson, D. and Eling, T. (1989). Mechanism of inhibition of prostaglandin H synthase by eugenol and other phenolic peroxidase substrates, Molecular Pharmacol. 36, 809–817.
Williams, H. J., Ward, J. R., Egger, M. J. et al. (1993). Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee, Arth. Rheum. 36, 1196–1206.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Graham, G.G., Day, R.O., Milligan, M.K. et al. Current concepts of the actions of paracetamol (acetaminophen) and NSAIDs. Inflammopharmacol 7, 255–263 (1999). https://doi.org/10.1007/s10787-999-0008-x
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/s10787-999-0008-x